Immune checkpoint inhibitors in malignancies after liver transplantation: A systematic review and pooled analysis.

Stefano KayaliAndrea PastaMaria Corina Plaz TorresAriel JaffeMario StrazzaboscoSimona MarencoEdoardo Giovanni Giannini

Published in: Liver international : official journal of the International Association for the Study of the Liver (2022)

Observational, off-label experience suggests that treatment with ICI for advanced malignancies in LT recipients might not be discarded a priori. This notwithstanding, ICI treatment in these patients is associated with a substantial risk of graft rejection and mortality. Prospective studies are needed to provide adequate safety and efficacy figures of ICI treatment in this fragile population.

Keyphrases

end stage renal disease
type diabetes
newly diagnosed
cardiovascular disease
combination therapy
coronary artery disease
cross sectional
peritoneal dialysis
prognostic factors
kidney transplantation
patient reported